ANN ARBOR, Mich., March 14, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the appointment of Dr. LaVonne Lang as head of regulatory affairs.
